Advertisement
Research Article Free access | 10.1172/JCI112080
Find articles by Caligaris-Cappio, F. in: JCI | PubMed | Google Scholar
Find articles by Bergui, L. in: JCI | PubMed | Google Scholar
Find articles by Tesio, L. in: JCI | PubMed | Google Scholar
Find articles by Pizzolo, G. in: JCI | PubMed | Google Scholar
Find articles by Malavasi, F. in: JCI | PubMed | Google Scholar
Find articles by Chilosi, M. in: JCI | PubMed | Google Scholar
Find articles by Campana, D. in: JCI | PubMed | Google Scholar
Find articles by van Camp, B. in: JCI | PubMed | Google Scholar
Find articles by Janossy, G. in: JCI | PubMed | Google Scholar
Published September 1, 1985 - More info
Precursors of plasma cells were studied in the bone marrow of 28 patients with multiple myeloma, plasma cell leukemia, and benign monoclonal gammopathy. Pre-B and B cell populations were analyzed with anti-B monoclonal antibodies corresponding to the clusters standardized at the Leucocyte Typing Workshops in Paris and Boston (CD9, CD10, CD19-22, CD24). In advanced forms of plasma cell malignancies, such as cases of multiple myeloma in stages II and III and of plasma cell leukemia, some cells of lymphoid morphology expressed common acute lymphoblastic leukemia antigen (CALLA, CD10) and HLA-DR, but contained no detectable terminal deoxynucleotidyl transferase enzyme. These CALLA+ cells were absent in benign monoclonal gammopathies. In multiple myeloma, the CALLA+ cells were negative for surface and cytoplasmic immunoglobulins (Ig), and, unlike CALLA+, terminal deoxynucleotidyl transferase (TdT+) pre-B cells in the normal bone marrow also failed to react with antibodies to B cell-associated antigens such as CD9, CD19, CD22, and CD24. The CALLA+, Ig- cells could be regarded as preplasmacytic since, after having been separated and stimulated with the phorbol ester 12-0-tetradecanoyl-phorbol-13 acetate in vitro, they transformed into plasma cells and synthesized the same heavy and light chains as myeloma cells.
Images.